Figure 3.
Treatment duration with BOR in efficacy-evaluable patients with CLL/SLL in cohorts 1 and 2. BOR, best overall response; nPR, nodular partial response; PD, progressive disease; PR-L, partial response with lymphocytosis.
Treatment duration with BOR in efficacy-evaluable patients with CLL/SLL in cohorts 1 and 2. BOR, best overall response; nPR, nodular partial response; PD, progressive disease; PR-L, partial response with lymphocytosis.
